| Identification | Back Directory | [Name]
SGL5213 | [CAS]
1240305-17-2 | [Synonyms]
SGL5213
SGL-5213,SGL5213
3-Butenamide, N-[2-[[2-(dimethylamino)ethyl]amino]-1,1-dimethyl-2-oxoethyl]-4-[4-[[5-β-D-glucopyranosyl-4-methoxy-2-(1-methylethyl)phenyl]methyl]phenyl]-2,2-dimethyl-, (3E)- | [Molecular Formula]
C37H55N3O8 | [MDL Number]
MFCD32067901 | [MOL File]
1240305-17-2.mol | [Molecular Weight]
669.85 |
| Hazard Information | Back Directory | [Uses]
SGL5213 is a potent, oral active and low-absorbable sodium-dependent glucose cotransporter 1 (SGLT1) inhibitor, with IC50 values of 29 nM and 20 nM for hSGLT1 and hSGLT2, respectively. SGL5213 has potential to treat type 2 diabetes treatment[1]. | [References]
[1] Kuroda S, et al. Discovery of potent, low-absorbable sodium-dependent glucose cotransporter 1 (SGLT1) inhibitor SGL5213 for type 2 diabetes treatment. Bioorg Med Chem. 2019 Jan 15;27(2):394-409. DOI:10.1016/j.bmc.2018.12.015 |
|
| Company Name: |
cjbscvictory
|
| Tel: |
13348960310 |
| Website: |
https://www.weikeqi-biotech.com/ |
|